연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
1451. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam B1, Im SA, Lim Y, Han SW, Moon HG, Oh DY, Cho N, Lee SH, Han W, Moon WK, Kim DW, Kim TY, Park IA, Noh DY.
Ann Surg Oncol. 2013 Jul;20(7):2242-9. doi: 10.1245/s10434-012-2756-x. Epub 2013 Mar 26.
Link
1450. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
Kim JW1, Cho HJ, Kim M, Lee KH, Kim MA, Han SW, Oh DY, Lee HJ, Im SA, Kim TY, Yang HK, Kim WH, Bang YJ.
Cancer Chemother Pharmacol. 2013 Jun;71(6):1435-43. doi: 10.1007/s00280-013-2141-x. Epub 2013 Apr 30.
Link
1449. RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.
Min A1, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, Kim HP, Lee KH, Han SW, Oh DY, Kim TY, O'Connor MJ, Kim WH, Bang YJ.
Mol Cancer Ther. 2013 Jun;12(6):865-77. doi: 10.1158/1535-7163.MCT-12-0950. Epub 2013 Mar 19.
Link
1448. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B1, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
Breast Cancer. 2013 Apr;20(2):167-73. doi: 10.1007/s12282-011-0323-0. Epub 2012 Feb 7.
Link
1447. Efficacy of exemestane in korean patients with metastatic breast cancer after failure of nonsteroidal aromatase inhibitors.
Lee JK1, Im SA, Lee D, Kim JY, Lim Y, Lee E, Moon HG, Kim TY, Han SW, Oh DY, Lee SH, Han W, Kim DW, Kim TY, Noh DY.
J Breast Cancer. 2013 Mar;16(1):66-71. doi: 10.4048/jbc.2013.16.1.66. Epub 2013 Mar 31.
Link
1446. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ1, Im SA, Oh DY, Elvin P, Kim HP, Yoon YK, Min A, Song SH, Han SW, Kim TY, Bang YJ.
Mol Cancer Ther. 2013 Jan;12(1):16-26. doi: 10.1158/1535-7163.MCT-12-0109. Epub 2012 Nov 9.
Link
1445. Impact of perioperative hemoglobin levels on postoperative outcomes in gastric cancer surgery.
Jung DH1, Lee HJ, Han DS, Suh YS, Kong SH, Lee KU, Yang HK.
Gastric Cancer. 2013 Jul;16(3):377-82. doi: 10.1007/s10120-012-0196-8. Epub 2012 Sep 25.
Link
1444. Laparoscopic gastrectomy for gastric cancer.
Lee HJ1, Yang HK.
Dig Surg. 2013;30(2):132-41. doi: 10.1159/000350884. Epub 2013 Jul 18.
Link
1443. Analysis of the Lymphatic Stream to Predict Sentinel Nodes in Gastric Cancer Patients.
Lee JH1, Lee HJ, Kong SH, Park DJ, Lee HS, Kim WH, Kim HH, Yang HK.
Ann Surg Oncol. 2013 Nov 26. [Epub ahead of print]
Link
1442. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Park JH1, Kim TM, Keam B, Jeon YK, Lee SH, Kim DW, Chung DH, Kim YT, Kim YW, Heo DS.
Clin Lung Cancer. 2013 Jul;14(4):383-9. doi: 10.1016/j.cllc.2012.10.007. Epub 2013 Jan 10.
Link